Todd Patrick, the former president of Vancouver, BC and Bothell, WA-based ID Biomedical, has been named the new CEO of Los Angeles-based C3 Jian. The company is developing selective antibacterial and antifungal treatments, as well as drugs for disorders of mineralization, and reversing hair loss. Patrick, the chairman of the board at the Seattle Biomedical Research Institute, was part of the executive team that sold ID Biomedical for $1.5 billion to GlaxoSmithKline in 2005.
Author: Luke Timmerman
Luke is an award-winning journalist specializing in life sciences. He has served as national biotechnology editor for Xconomy and national biotechnology reporter for Bloomberg News. Luke got started covering life sciences at The Seattle Times, where he was the lead reporter on an investigation of doctors who leaked confidential information about clinical trials to investors. The story won the Scripps Howard National Journalism Award and several other national prizes. Luke holds a bachelor’s degree in journalism from the University of Wisconsin-Madison, and during the 2005-2006 academic year, he was a Knight Science Journalism Fellow at MIT.
View all posts by Luke Timmerman
